The International Association for the Study of Lung Cancer
The IASLC is a global multidisciplinary organization dedicated to eradication of all forms of lung cancer. From provision of educational events around the world and virtually to research projects and publications that advance the science of lung cancer, the IASLC's members—consisting of medical, surgical, and radiation oncologists, as well as other thoracic oncology specialists such as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient research advocates, patients, and their caregivers—are raising the bar for care of patients with lung cancer.
In Focus
ILCN Molecular Challenges Forum: ALK Pioneers and Progress
ALK research and therapy has evolved substantially since the original PROFILE 1001 study, which first evaluated crizotinib for patients with ALK-rearranged NSCLC. Patient advocate and ALK-positive survivor of more than 15 years, Linnea Olsen, was the fourth person in the world to go on that trial. Now, after more than a decade of research and six-phase I trials, Linnea shares her experiences with newer therapies and thoughts on the importance of being NED (no evidence of disease) vs. NDY (“not dead yet”). Moderator Ross Camidge, MD, and panelist Jessica Lin, MD, who is Linnea’s oncologist, provide expert perspectives on the current and future standards of care for patients with ALK-rearranged NSCLC and on what it is like living with lung cancer for more than a decade.
Our Impact
8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.
Our Impact
8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.
Latest News
Our Work
In Numbers
8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.
Upcoming Meetings & Webinars
Journal of Thoracic Oncology & JTO Clinical and Research Reports
Lung and thoracic specialists count on the IASLC’s journals to provide perspective on innovation in prevention, detention, diagnosis and cutting-edge treatments. As a leading medical journal, JTO focuses on lung and thoracic cancers and is dedicated to presenting original research reviews and opinions from a wide range of disciplines within the medical community. JTO CRR, the official open access journal of the IASLC, complements the JTO by offering authors a gold open access publication option.